rhythm - Search News

News

Rhythm, obesity and Phases of clinical research

Rhythm’s phase 2 obesity pill trial hits primary endpoint, sending stock up

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. A phase 2 trial of the biotech’s next-generation oral candidate hit its primary endpoint,

GlobalData on MSN · 1d

Rhythm’s stock climbs on encouraging Phase II obesity drug data

InvestorsHub on MSN · 1d

Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug

Investor's Business Daily on MSN1d

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat a rare form ...

17h

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm Pharma Shares Gain on Positive Results From Recent Trial of Obesity Treatment

Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...

Devdiscourse1d

Dum: An Auditory Invocation of Rhythm and Roots

Dum is a mesmerizing auditory journey crafted by rhythm maestros Bickram Ghosh and Taufiq Qureshi. This avant-garde piece ...

1don MSN

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.